Page last updated: 2024-11-04

temozolomide and Hyperprolactinaemia

temozolomide has been researched along with Hyperprolactinaemia in 3 studies

Research Excerpts

ExcerptRelevanceReference
"We report here a rare case of a young male patient presenting with a Multiple Endocrine Neoplasia Type 1 - prolactin-secreting pituitary carcinoma, controlled long-term after temozolomide withdrawal."7.78Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment. ( Barlier, A; Barrie, M; Brue, T; Castinetti, F; Conte-Devolx, B; Dufour, H; Morange, I; Philippon, M; Taieb, D, 2012)
"We report here a rare case of a young male patient presenting with a Multiple Endocrine Neoplasia Type 1 - prolactin-secreting pituitary carcinoma, controlled long-term after temozolomide withdrawal."3.78Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment. ( Barlier, A; Barrie, M; Brue, T; Castinetti, F; Conte-Devolx, B; Dufour, H; Morange, I; Philippon, M; Taieb, D, 2012)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Wildemberg, LE1
Fialho, C1
Gadelha, MR1
Bilbao, I1
Egaña, N1
García, C1
Olaizola, I1
Philippon, M1
Morange, I1
Barrie, M1
Barlier, A1
Taieb, D1
Dufour, H1
Conte-Devolx, B1
Brue, T1
Castinetti, F1

Reviews

1 review available for temozolomide and Hyperprolactinaemia

ArticleYear
Prolactinomas.
    Presse medicale (Paris, France : 1983), 2021, Volume: 50, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agon

2021

Other Studies

2 other studies available for temozolomide and Hyperprolactinaemia

ArticleYear
Failure of a second temozolomide cycle in a patient with a prolactin-secreting pituitary carcinoma.
    Endocrinologia, diabetes y nutricion, 2017, Volume: 64, Issue:10

    Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bromocriptine; Cabergoline; Combined

2017
Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment.
    Annales d'endocrinologie, 2012, Volume: 73, Issue:3

    Topics: Adult; Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Cranial Irradiation; Dacarbazine

2012